OIG: Medicaid could save $1.4 billion by requiring rebates from generic drug makers

Share this content:
Generic drug prices outpaced inflation in 22% of the medications studied.
Generic drug prices outpaced inflation in 22% of the medications studied.

Requiring generic drug makers to pay rebates when they raised prices faster than inflation would have trimmed $1.4 billion from Medicaid outlays over the past decade, notes a report from the Office of Inspector General.

Auditors found that generic drug prices outpaced inflation in 22% of the medications they examined for the study. Branded medications are already required to issue rebates when this happens.

The OIG encouraged the Centers for Medicare & Medicaid Services to consider seeking legislative authority that would extend the same rule to companies making generic drugs.


close

Next Article in News

In Focus

May 16

Bringing in the outdoors

Hollidaysburg, PA 

Garvey Manor and Our Lady of the Alleghenies Residence continuing care retirement community recently hosted an outdoor show, "Marching into the Woods."

JOB LISTINGS